Literature DB >> 26274795

The role of matching when adjusting for baseline differences in the outcome variable of comparative effectiveness studies.

Carlos G Grijalva1,2, Christianne L Roumie2,3, Harvey J Murff2,3, Adriana M Hung2,3, Cole Beck4, Xulei Liu2,4, Marie R Griffin1,2,3, Robert A Greevy2,4.   

Abstract

AIM: Evaluate performance of analytical strategies commonly used to adjust for baseline differences in continuous outcome variables for comparative effectiveness studies. PATIENTS &
METHODS: Data simulations resembling a comparison of HbA1c values after initiation of antidiabetic treatments adjusting for baseline HbA1c. We evaluated change scores, analyses of covariance including linear, nonlinear with/without robust variance estimations, before and after optimal matching. We also evaluated the impact of measurement error.
RESULTS: With increasing HbA1c baseline differences between groups, bias in effect estimates and suboptimal CI coverage probabilities increased in all approaches. These issues were further compounded by measurement error. Matching on baseline HbA1c, substantially mitigated these issues.
CONCLUSION: In comparative studies with continuous outcomes, matching on baseline values of the outcome variable improves analytical performance.

Entities:  

Keywords:  baseline adjustment; comparative effectiveness; diabetes; glycated hemoglobin; matching

Mesh:

Substances:

Year:  2015        PMID: 26274795      PMCID: PMC4699664          DOI: 10.2217/cer.15.16

Source DB:  PubMed          Journal:  J Comp Eff Res        ISSN: 2042-6305            Impact factor:   1.744


  14 in total

Review 1.  Statistics notes: Analysing controlled trials with baseline and follow up measurements.

Authors:  A J Vickers; D G Altman
Journal:  BMJ       Date:  2001-11-10

2.  Change from baseline and analysis of covariance revisited.

Authors:  Stephen Senn
Journal:  Stat Med       Date:  2006-12-30       Impact factor: 2.373

3.  Immortal time bias in observational studies of drug effects.

Authors:  Samy Suissa
Journal:  Pharmacoepidemiol Drug Saf       Date:  2007-03       Impact factor: 2.890

4.  Analytic bias among certified methods for the measurement of hemoglobin A1c: a cause for concern?

Authors:  Earle W Holmes; Cağatay Erşahin; Geri J Augustine; Gerald A Charnogursky; Margie Gryzbac; Joanne V Murrell; Kathleen M McKenna; Fadi Nabhan; Stephen E Kahn
Journal:  Am J Clin Pathol       Date:  2008-04       Impact factor: 2.493

5.  Accounting for baseline differences and measurement error in the analysis of change over time.

Authors:  Julia Braun; Leonhard Held; Bruno Ledergerber
Journal:  Stat Med       Date:  2013-07-30       Impact factor: 2.373

6.  A paradox in the interpretation of group comparisons.

Authors:  F M Lord
Journal:  Psychol Bull       Date:  1967-11       Impact factor: 17.737

7.  Comparing groups in a before-after design: when t test and ANCOVA produce different results.

Authors:  Daniel B Wright
Journal:  Br J Educ Psychol       Date:  2006-09

8.  A regularization corrected score method for nonlinear regression models with covariate error.

Authors:  David M Zucker; Malka Gorfine; Yi Li; Mahlet G Tadesse; Donna Spiegelman
Journal:  Biometrics       Date:  2013-02-04       Impact factor: 2.571

9.  Optimal Nonbipartite Matching and Its Statistical Applications.

Authors:  Bo Lu; Robert Greevy; Xinyi Xu; Cole Beck
Journal:  Am Stat       Date:  2012-01-01       Impact factor: 8.710

10.  Hidden complexities in assessment of glycemic outcomes: are quality rankings aligned with treatment?

Authors:  Leonard M Pogach; Mangala Rajan; Miriam Maney; Chin-Lin Tseng; David C Aron
Journal:  Diabetes Care       Date:  2010-07-09       Impact factor: 19.112

View more
  2 in total

1.  The importance of health insurance claims data in creating learning health systems: evaluating care for high-need high-cost patients using the National Patient-Centered Clinical Research Network (PCORNet).

Authors:  Maureen A Smith; Mary S Vaughan-Sarrazin; Menggang Yu; Xinyi Wang; Peter A Nordby; Christine Vogeli; Jonathan Jaffery; Joshua P Metlay
Journal:  J Am Med Inform Assoc       Date:  2019-11-01       Impact factor: 4.497

2.  Metastatic progression following multimodal therapy for unfavorable-risk prostate cancer.

Authors:  David Guy; Rachel Glicksman; Roger Buckley; Patrick Cheung; Hans Chung; Stanley Flax; David Hajek; Andrew Loblaw; Gerard Morton; Jeffery Noakes; Les Spevack; Joseph L K Chin; George Rodrigues
Journal:  Can Urol Assoc J       Date:  2022-04       Impact factor: 2.052

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.